Literature DB >> 18358796

Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.

R Berni Canani1, G Terrin, L Rapacciuolo, E Miele, M C Siani, C Puzone, L Cosenza, A Staiano, R Troncone.   

Abstract

BACKGROUND: An accurate monitoring of mucosal inflammation is important for an effective management of patients with inflammatory bowel disease. Intestinal inflammation can be detected by faecal calprotectin level determination. AIM: To comparatively evaluate the accuracy of faecal calprotectin, clinical scores, common serum markers and endoscopy in the assessment of the severity of intestinal mucosa inflammation in children with inflammatory bowel disease.
METHODS: Fifty-eight paediatric patients (mean age 13.9 years, 95% CI 2.9-14.8; male 28) with confirmed inflammatory bowel disease (26 Crohn's disease, 32 ulcerative colitis) were enrolled. Before endoscopy, all patients underwent a complete evaluation including: clinical scores, erythrocyte sedimentation rate, C-reactive protein and faecal calprotectin determination. The severity of mucosal inflammation was assessed using specific endoscopic and histologic scores.
RESULTS: Faecal calprotectin showed a high correlation (r=0.655) with the histologic grade of mucosal inflammation, similar to that observed for endoscopy (r=0.699), and it resulted the most accurate tool (sensitivity 94%, specificity 64%, positive predictive value 81%, negative predictive value 87%) to detect the presence of active mucosal inflammation when compared to clinical scores and common serum markers. In patients with apparent clinical and laboratory remission the accuracy of faecal calprotectin resulted further improved (sensitivity 100%, specificity 80%, positive predictive value 67%, negative predictive value 100%).
CONCLUSIONS: A more accurate assessment of the severity of mucosal inflammation can be achieved by the determination of faecal calprotectin levels compared to other common clinical and laboratory indices. This non-invasive and objective method could be particular useful in patients with apparent clinical and laboratory remission.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18358796     DOI: 10.1016/j.dld.2008.01.017

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  49 in total

1.  Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis.

Authors:  Tarang Taghvaei; Iradj Maleki; Farshad Nagshvar; Hafez Fakheri; Vahid Hosseini; Seyed Mohammad Valizadeh; Hassan Neishaboori
Journal:  Intern Emerg Med       Date:  2014-11-04       Impact factor: 3.397

Review 2.  Role of conventional therapies in the era of biological treatment in Crohn's disease.

Authors:  Paolo Gionchetti; Carlo Calabrese; Rosy Tambasco; Ramona Brugnera; Giulia Straforini; Giuseppina Liguori; Giulia Spuri Fornarini; Donatella Riso; Massimo Campieri; Fernando Rizzello
Journal:  World J Gastroenterol       Date:  2011-04-14       Impact factor: 5.742

Review 3.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

Review 4.  Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.

Authors:  Anke Heida; K T Park; Patrick F van Rheenen
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

5.  Intestinal protein expression profile identifies inflammatory bowel disease and predicts relapse.

Authors:  Jun Shen; Yuqi Qiao; Zhihua Ran; Tianrong Wang; Jiangtao Xu; Jinsun Feng
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

Review 6.  Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease.

Authors:  Anastassios C Manolakis; Andreas N Kapsoritakis; Elisavet K Tiaka; Spyros P Potamianos
Journal:  Dig Dis Sci       Date:  2011-01-04       Impact factor: 3.199

7.  Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels.

Authors:  Anssi Hämäläinen; Taina Sipponen; Kaija-Leena Kolho
Journal:  World J Gastroenterol       Date:  2011-12-21       Impact factor: 5.742

8.  Geophagy is associated with environmental enteropathy and stunting in children in rural Bangladesh.

Authors:  Christine Marie George; Lauren Oldja; Shwapon Biswas; Jamie Perin; Gwenyth O Lee; Margaret Kosek; R Bradley Sack; Shahnawaz Ahmed; Rashidul Haque; Tahmina Parvin; Ishrat J Azmi; Sazzadul Islam Bhuyian; Kaisar A Talukder; Shahnaij Mohammad; Abu G Faruque
Journal:  Am J Trop Med Hyg       Date:  2015-04-27       Impact factor: 2.345

Review 9.  Probiotic supplementation in children with cystic fibrosis-a systematic review.

Authors:  Anitha Ananthan; Haribalakrishna Balasubramanian; Shripada Rao; Sanjay Patole
Journal:  Eur J Pediatr       Date:  2016-08-30       Impact factor: 3.183

10.  Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.

Authors:  Jernej Dolinšek; Petra Rižnik; Larisa Sabath; Dušanka Mičetić-Turk
Journal:  Wien Klin Wochenschr       Date:  2015-12-10       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.